Skip to main content

Table 3 Distribution of outcomes after discontinuation of lamivudine, adefovir, entecavir, and telbivudine

From: Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative

NUCs Sustained response - no. (%) Relapse - no. (%)
LAM 11 (24.4) 2 (10.5)
ADV 27 (60.0) 15 (78.9)
ETV 5 (11.1) 2 (10.5)
LDT 2 (4.4) 0
  1. LAM, lamivudine; ADV, adefovir; ETV, entecavir; LDT, telbivudine.